Navigation Links
UTMB named a World Health Organization Collaborating Center for Vaccine Research
Date:8/15/2014

The world experts on vaccine development at the University of Texas Medical Branch at Galveston have received an international designation acknowledging their unique niche in a sphere where research, government regulation and big pharma often collide.

UTMB's Sealy Center for Vaccine Development has been named a World Health Organization Collaborating Center for Vaccine Research, Evaluation and Training on Emerging Infectious Diseases. The designation by WHO makes UTMB only the second university in the Western Hemisphere to receive this designation; the other is the Johns Hopkins Bloomberg School of Public Health.

This means that UTMB's vaccine development experts will collaborate with a select team of international experts to help facilitate vaccine research and development against important infectious diseases for example, figuring out how to get experimental Ebola vaccine candidates to suffering people in the wake of the recent outbreak.

"UTMB's top-tier expertise in vaccine development is acknowledged among scientists across the globe," said Joachim Hombach, senior adviser, Immunization, Vaccines and Biologicals at WHO and co-director of the Global Vaccine and Immunization Research Forum. "Especially regarding emerging infectious diseases that represent a significant cause of suffering and death, and impose an enormous financial burden on society, UTMB is clearly recognized as one of the most important international leaders in the vaccine development world."

The medical branch is only the seventh university in the world to receive WHO designation for vaccine expertise. In addition to the Johns Hopkins Bloomberg School of Public Health, the others are the University of Geneva, University of Zurich, and University of Lausanne in Switzerland, the Second Military Medical University in Shanghai and the University of Antwerp in Belgium.

"UTMB fills a critical role at the intersection of biocontainment and emerging dise
'/>"/>

Contact: Molly Dannenmaier
mjdannen@utmb.edu
409-772-8790
University of Texas Medical Branch at Galveston
Source:Eurekalert

Page: 1 2

Related biology news :

1. UTHealths Dr. William Margolin named distinguished lecturer for microbiology
2. UH professor named 2014 American Chemical Society Cope Scholar
3. California State Senator Darrell Steinberg named as ESA Regional Policy Award winner
4. New mite species from a Caribbean mesophotic coral ecosystem named after J.Lo
5. Arizona State faculty member named Howard Hughes Medical Institute Professor
6. Victor Ambros named co-recipient of 2014 Gruber Genetics Prize
7. New grasshopper species named after Grammy winner
8. ICRAF scientist named AfriCAN Climate Research Award winner
9. UH student named Goldwater Scholar, 2 more receive honorable mention
10. Orchid named after UC Riverside researcher
11. Energy Systems Integration Facility named Lab of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... -- You,ve been here before: you desperately need to sign ... site key or the answer to your secret question. What,s ... Today, Hoyos Labs , a digital infrastructure ... put an end to the frustration that comes with usernames, ... leverages a user,s smartphone to acquire his or her biometrics ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/4/2014)... PALM BEACH GARDENS, Fla. , Dec. 3, ... identity management solutions, today announced that its DigitalPersona ... 4500 fingerprint readers have been deployed throughout ... Carolina , South Carolina ... network headquartered in Southern Pines, North ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... food becomes scarce, animal populations exploit a wider range ... at different sites in California,s coastal waters were not ... population is higher where food is limited. But this ... sea otters, which instead showed dietary specialization in response ...
... some of the genetic secrets that enable pine ... disease, uncovering critical new information about forests natural ... this genetic analysis will allow forest stewardship programs ... that could in time repel insects such as ...
... --- Mother Nature regulates critical cellular activities in plants ... specific biochemical reactions. Looking to learn from nature, a ... million grant from the Air Force Office of Scientific ... for military and civilian applications. The grant ...
Cached Biology News:Sea otter study reveals striking variability in diets and feeding strategies 2Sea otter study reveals striking variability in diets and feeding strategies 3UBC discovery unlocks tree genetics, gives new hope for pine beetle defense 2Team of chemists receives $5 million grant to develop enzyme mimics 2
(Date:12/17/2014)... BASKING RIDGE, N.J. (PRWEB) December 17, 2014 ... Ipsen (Euronext: IPN; ADR: IPSEY), ... 120 mg (referred to as Somatuline®) was approved ... for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) ... differentiated, locally advanced or metastatic disease to improve ...
(Date:12/17/2014)... 2014 Xeno Diagnostics has again ... most recent COLA inspection. Xeno has met all ... healthcare accreditation organization. Accreditation is earned only by ... day-to-day operations, demonstrate continued accuracy in the performance ... laboratory survey. , While the Laboratory ...
(Date:12/17/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... announced the next step in its expanded strategy to ... with the naming of current Chief Operating Officer, ... while current Chairman of the Board and CEO ... These changes are effective January 1, 2015. ...
(Date:12/17/2014)... SAN FRANCISCO, Calif. , Dec. 17, 2014 ... results of a Phase 2 study evaluating the ... the treatment of patients with severe, chronic itch ... current standard of care, including topical steroids and ... was percent change in Visual Analog Scale (VAS) ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... Inc. (Nasdaq: EMIS ) has agreed to ... LLY ) to settle the pending litigation ... submit a Stipulation of Dismissal with,Prejudice of their ... the,Southern District of Indiana. Additional terms and conditions ...
... Morria Biopharmaceuticals Plc, a,private biopharmaceutical company ... announced it has appointed Dr.,Johnson Lau and ... directors. Dr. Johnson Lau (MBBS, MD, ... the,medical, pharmaceutical and corporate fields, having a ...
... f-star, an antibody,engineering company developing novel antibodies ... Antibody Technology, today announced the,appointment of Dr. ... Mudde has,over 20 years of experience in ... research and development. He comes to f-star,from ...
Cached Biology Technology:Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation 2Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors 2Antibody Engineering Company f-Star Appoints Geert Mudde as Chief Scientific Officer 2
... StabilZyme HRP Conjugate Stabilizer is an aqueous ... and other non-toxic stabilizing chemicals in a ... 6.7. This product contains a ... 20 ppm Proclin 300 (Rohm and Haas ...
Preparation Note: Prepared by method of Wimmer, E., et al., Biochemistry, 7, 2623 (1968). Quality Clarifier: Acceptor Activity: approx. 1000 picomoles phenylalanine per A 260 unit (not determined b...
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
... V-106 voice-coil scanning and positioning system ... samples have to be positioned or ... resolution. It provides superior responsiveness compared ... The mechanics (X or XY stage) ...
Biology Products: